Laninamivir-Interferon Lambda 1 Combination Treatment Promotes Resistance by Influenza A Virus More Rapidly than Laninamivir Alone
- 1 July 2020
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 64 (7)
- https://doi.org/10.1128/AAC.00301-20
Abstract
Each year, 5% to 20% of the population of the United States becomes infected with influenza A virus. Combination therapy with two or more antiviral agents has been considered a potential treatment option for influenza virus infection. However, the clinical results derived from combination treatment with two or more antiviral drugs have been variable. We examined the effectiveness of cotreatment with two distinct classes of anti-influenza drugs, i.e., neuraminidase (NA) inhibitor, laninamivir, and interferon lambda 1 (IFN-lambda 1), against the emergence of drug-resistant virus variants in vitro. We serially passaged pandemic A/California/04/09 [A(H1N1)pdm09] influenza virus in a human lung epithelial cell line (Calu-3) in the presence or absence of increasing concentrations of laninamivir or laninamivir plus IFN-lambda 1. Surprisingly, laninamivir used in combination with IFN-lambda 1 promoted the emergence of the E119G NA mutation five passages earlier than laninamivir alone (passage 2 versus passage 7, respectively). Acquisition of this mutation resulted in significantly reduced sensitivity to the NA inhibitors laninamivir (similar to 284-fold) and zanamivir (similar to 1,024-fold) and decreased NA enzyme catalytic activity (similar to 5-fold) compared to the parental virus. Moreover, the E119G NA mutation emerged together with concomitant hemagglutinin (HA) mutations (T197A and D222G), which were selected more rapidly by combination treatment with laninamivir plus IFN-lambda 1 (passages 2 and 3, respectively) than by laninamivir alone (passage 10). Our results show that treatment with laninamivir alone or in combination with IFN-lambda 1 can lead to the emergence of drug-resistant influenza virus variants. The addition of IFN-lambda 1 in combination with laninamivir may promote acquisition of drug resistance more rapidly than treatment with laninamivir alone.Keywords
This publication has 55 references indexed in Scilit:
- Mutations in PA, NP, and HA of a pandemic (H1N1) 2009 influenza virus contribute to its adaptation to miceVirus Research, 2011
- Generation and Characterization of Recombinant Pandemic Influenza A(H1N1) Viruses Resistant to Neuraminidase InhibitorsThe Journal of Infectious Diseases, 2011
- Virulence-Associated Substitution D222G in the Hemagglutinin of 2009 Pandemic Influenza A(H1N1) Virus Affects Receptor BindingJournal of Virology, 2010
- Adaptation of Pandemic H1N1 Influenza Viruses in MiceJournal of Virology, 2010
- Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir ResistanceScience, 2010
- Lambda Interferon Renders Epithelial Cells of the Respiratory and Gastrointestinal Tracts Resistant to Viral InfectionsJournal of Virology, 2010
- Structural Basis of Preexisting Immunity to the 2009 H1N1 Pandemic Influenza VirusScience, 2010
- Zanamivir-Resistant Influenza Viruses with a Novel Neuraminidase MutationJournal of Virology, 2009
- Universal primer set for the full-length amplification of all influenza A virusesArchiv für die gesamte Virusforschung, 2001
- A DNA transfection system for generation of influenza A virus from eight plasmidsProceedings of the National Academy of Sciences of the United States of America, 2000